Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kinect

- PMLiVE

Novartis restructures organisation to support growth and innovation

The new operational structure will involve integrating pharmaceuticals and oncology business units into an Innovative Medicines business

- PMLiVE

Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients

There are an estimated 130,000 people with MS in the UK

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

- PMLiVE

Novartis and Voyager Therapeutics agree on gene therapy deal worth 1.7bn

The licence option agreement is for next-generation gene therapy vectors for neurological diseases

- PMLiVE

Novartis to pay up to $1.5bn for Gyroscope

The acquisition of ocular gene therapy company, Gyroscope, adds GT005 to the Novartis portfolio – a one-time gene therapy for geographic atrophy, a leading cause of blindness

- PMLiVE

Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn

Novartis is to pay $300m upfront to BeiGene in a multifaceted deal to enhance its oncology portfolio and expand coverage of the Chinese market

- PMLiVE

Novartis pulls out of Mesoblast deal

Shares in Mesoblast dropped sharply after Novartis pulled out of a deal announced earlier this year to collaborate on COVID-19 medicine remestemcel-L, citing poor trial data

- PMLiVE

Roche and Novartis part ways with share purchase

Novartis is to sell its one-third stake in Roche for more than $20bn, paving the way for potential acquisitions

- PMLiVE

Novartis invests $1.3bn in protein degradation technology

Novartis will work with UK-based start-up Dunad Therapeutics to develop protein degradation drugs

- PMLiVE

Novartis receives approval for third-generation leukaemia therapy

With a novel mechanism of action, Scemblix is a new option for people with chronic myeloid leukaemia who experience intolerance or inadequate response to standard therapy

- PMLiVE

Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz

The company has started a strategic review of Sandoz as sales drop 20% in ‘challenging’ US market

- PMLiVE

NICE recommends Novartis’ Adakveo for sickle cell disease

The treatment for sickle cell disease is the first in more than 20 years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links